Apnimed

Quick facts

Marketed products

• Period B · Sleep disorders
  Period B is a melatonin receptor agonist that helps regulate sleep-wake cycles.

Phase 3 pipeline

• AD109 · Oncology
  AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation.
• Aroxybutynin and Atomoxetine · Urology/Neurology
  This combination drug blocks muscarinic acetylcholine receptors (via oxybutynin component) and inhibits norepinephrine reuptake (via atomoxetine component) to reduce urinary incontinence and improve attention.

Phase 2 pipeline

• AD036 · Neurology
  AD036 is a small molecule that targets the orexin receptor to treat narcolepsy.
• AD109 dose1- A · Neurology
  AD109 is a small molecule that targets the orexin receptor to treat narcolepsy.
• AD109 dose2- B · Neurology
  AD109 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.
• AD113
• AD182 · Neurology
  AD182 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.
• AD504 · Neurology
  AD504 is an oral small molecule that targets the orexin receptor to treat narcolepsy.
• Period A
• Period C
• R-oxybutynin

Phase 1 pipeline

• AD313
• Dosing 1: Atomoxetine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Apnimed portfolio CI brief
• Apnimed pipeline updates RSS